• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.


Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
Application Number P110008
Current Protocol Accepted 04/23/2013
Study Name OSB Lead-Coflex Long-Term PAS
Study Status Progress Inadequate
Study Progress Reason More than 10% of the primary endpoint data missing
General Study Protocol Parameters
Study Design Randomized Clinical Trial
Study involve follow-up of premarket cohort (Y/N) Yes
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description Randomized clinical trial
Study Population Description The study population is comprised of patients who received the device during the IDE or   show the rest ...
Sample Size A total of 191 coflex and 104 fusion patients comprise the sample size.
Data Collection The following criteria will be used to evaluate CCS at each post year 2 follow-up   show the rest ...
Followup Visits and Length of Followup 5 years.
Patients in the long-term follow-up study will be asked to
return for follow-up evaluations annually   show the rest ...

OSB Lead-Coflex Long-Term PAS Schedule

Report Schedule
Date Due
FDA Receipt
Reporting Status
six month report 04/17/2013 07/05/2013 Overdue/Received
one year report 12/01/2013 02/20/2014 Overdue/Received
18 month report 04/17/2014 06/02/2014 Overdue/Received
two year report 10/17/2014 10/20/2014 Overdue/Received
three year report-Final Report 11/17/2015   Overdue

Show All Studies